Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma
- Patient with diffuse large B-cell lymphoma according to the WHO classification (anti
- Aged 18 to 60 years
- Non previously treated
- With one and only one of the following adverse characteristics: ECOG performance
status 2 or more, or Ann Arbor stage III or IV, or elevated LDH level
- Negative HIV, HBV and HCV serologies (except vaccination)
- With a minimum life expectancy of 3 months
- Having previously signed a written informed consent
- Any history of treated or non-treated indolent lymphoma.
- T-cell lymphoma.
- Central nervous system or meningeal involvement by lymphoma.
- Any Contra-indication to any drug contained in the chemotherapy regimens.
- Poor renal function (creatinin level>150µmol/l), poor hepatic function (total
bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these
abnormalities are related to the lymphoma.
- Serious active disease (according to the investigator’s decision).
- Poor bone marrow reserve as defined by neutrophils <1.5G/l or platelets<100G/l,
unless related to bone marrow infiltration.
- Any history of cancer during the last 5 years with the exception of non-melanoma skin
tumors or stage 0 (in situ) cervical carcinoma.
- Treatment with any investigational drug within 30 days before planned first cycle of
chemotherapy and during the study.
- Childbearing woman.
- Patients previously treated with an organ transplantation.